Midostaurin 25 mg capsules, 28 capsules — generic (India) (Rydapt-equivalent) Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) +380996042415

Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent active against a variety of solid and hematopoietic tumors.4 It was approved on April 28, 2017, and has demonstrated improved overall survival in patients with AML as adjuvant therapy alongside chemotherapy.